Radionuclide therapy for bone metastases by drugs based on Re-188

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• Systemic radionuclide therapy with bone-seeking agents is effective for palliative bone treatment.
• Radiolabeled bisphosphonates and strontium-89 demonstrate significant pain reduction (70-80%) and pain-free outcomes (20%) in patients.
• Rhenium-188 (Re-188) is a promising radionuclide for bone pain palliation due to its availability and cost-effectiveness.

Purpose of the Study:

• To evaluate the efficacy and safety of rhenium-188 (Re-188) based radiopharmaceuticals for bone pain palliation.
• To compare Re-188 radiopharmaceuticals with existing bone-seeking radionuclide therapies.
• To highlight novel Re-188 drug developments for bone metastases treatment.

Main Methods:

• Review of studies utilizing radiolabeled bisphosphonates, strontium-89, and rhenium-188 (Re-188) for bone pain palliation.
• Analysis of clinical data on Re-188 HEDP for efficacy, toxicity, and survival outcomes.
• Examination of alpha emitter therapy (Radium-223) in prostate cancer bone metastases.
• Inclusion of Russian-developed Re-188 drugs: Phosphoren and Re-188-zoledronic acid (Zoleren).

Main Results:

• Re-188 radiopharmaceuticals exhibit comparable effectiveness and bone marrow toxicity to established bisphosphonates.
• Repeat treatments with rhenium-188 HEDP showed a trend towards increased survival.
• Radium-223 therapy in prostate cancer patients with bone metastases resulted in a 3.6-month survival prolongation compared to placebo.
• Phosphoren demonstrated similar properties to Re-188-HEDP in clinical studies.
• Re-188-zoledronic acid combines the therapeutic benefits of zoledronic acid and Re-188.

Conclusions:

• Rhenium-188 (Re-188) radiopharmaceuticals are effective and cost-efficient options for bone pain palliation.
• Novel Re-188 formulations offer advanced therapeutic potential for bone metastases.
• Alpha emitter therapy, such as Radium-223, shows survival benefits in specific cancer types with bone involvement.